This article first appeared on GuruFocus.
-
Total Income: $50.6 million, a 15% year-over-year increase.
-
Royalty Income Growth: 18% increase, contributing to total income growth.
-
Adjusted EBITDA Margin: 90%, normalized to 91% excluding non-recurring costs.
-
Cash Receipts: $58.4 million, a 6% decrease year-over-year.
-
Adjusted Cash Earnings Per Unit: $0.68.
-
Quarterly Distribution: $0.11 per unit, payable on July 20, 2026.
-
Cash and Cash Equivalents: $52.5 million as of March 31, 2026.
-
Credit Availability: $502.7 million from bank facilities.
-
Adjusted EBITDA (Trailing 12 Months): $166.1 million with an 86% margin.
-
Adjusted Cash Earnings Per Unit (Trailing 12 Months): $2.51.
-
Unit Buybacks: 76,000 units acquired and canceled at an average price of $11.31 during Q1 2026.
Release Date: May 15, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
DRI Healthcare Trust (DHTRF) reported a double-digit royalty income growth of 18%, contributing to a total income of $50.6 million, marking a 15% year-over-year growth.
-
The company achieved a first-quarter adjusted EBITDA margin of 90%, setting a company record.
-
DRI Healthcare Trust (DHTRF) successfully completed two financing transactions, strengthening its balance sheet and positioning the company for long-term success.
-
The company reduced its preferred shares outstanding by partially redeeming and canceling $9.9 million of face value of Series C preferred securities.
-
DRI Healthcare Trust (DHTRF) entered the US private placement market, diversifying access to capital and opening a new source of long-term institutional financing.
Negative Points
-
Total cash receipts for the first quarter of 2026 decreased by 6% compared to Q1 2025, driven by a one-time payment in the previous year and lower receipts from certain products.
-
Spinraza cash receipts were down 8% year-over-year due to lower demand and competition from Roche’s products.
-
The company recognized a loss on debt refinancing of $9.8 million related to the preferred securities conversion.
-
DRI Healthcare Trust (DHTRF) anticipates a slight decrease in operating margins beginning in Q2 due to reinvestment of synergies back into the business.
-
The company faced softer performance from certain assets like Bonzhou, Rydapt, and Aratia, partially offsetting strong comps from other products.
Q & A Highlights
Q: Can you expand on the potential change of control with the KalVista acquisition by Chiale Group and its impact on DRI Healthcare Trust? A: Ali Hedayat, Acting CEO, mentioned that they are still evaluating the situation and have limited information beyond public announcements. They are assessing what is optimal for DRI and have not made any determinations regarding the change of control implications.
